82 
Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention
Bio Pharma Dive
SEPTEMBER 17, 2021
The expanded authorization comes amid surging demand for antibody treatments, particularly in states with lower rates of coronavirus vaccination
Antibody Related Topics 
Regeneron antibody cuts risk of COVID-19 death in UK study
Bio Pharma Dive
JUNE 16, 2021
The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Unexpected antibody type found in people with malaria infections
Scienmag
NOVEMBER 2, 2021
However, in a newly published study, researchers at the University of Maryland School of Medicine (UMSOM) have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as […].
Who would get Regeneron's COVID-19 antibody treatment?
Bio Pharma Dive
NOVEMBER 5, 2020
Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.
Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug
Bio Pharma Dive
NOVEMBER 9, 2020
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact
FDA clears Lilly's COVID-19 antibody cocktail for emergency use
Bio Pharma Dive
FEBRUARY 10, 2021
In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death
Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody
Bio Pharma Dive
JUNE 18, 2021
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.
PKU researchers harness higher order protein catenation for the development of artificial antibodies
Scienmag
NOVEMBER 17, 2021
Mathematics Antibodies Artificial catenation development harness Higher order PKU protein researchersChemical topology is a unique dimension for protein engineering.
A startup raises $336M to make a better antibody drug for COVID-19
Bio Pharma Dive
APRIL 19, 2021
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests
J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies
Bio Pharma Dive
MAY 24, 2021
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors
Horse hyperimmune antibody may help the fight against COVID-19, Brazilian study finds
Scienmag
OCTOBER 26, 2021
A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat covid-19.
COVID vaccine booster increases antibody responses, is protective in rhesus macaques
Scienmag
OCTOBER 21, 2021
Medicine & Health antibody booster COVID increases macaques protective responses rhesus vaccine
US stops rollout of Lilly's first COVID-19 antibody over variant concerns
Bio Pharma Dive
MARCH 25, 2021
Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials
|
FDA approves Regeneron antibody drug as first Ebola virus treatment
Bio Pharma Dive
OCTOBER 14, 2020
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19
COVID antibodies from Roche, Celltrion backed for approval in EU
Pharma Phorum
NOVEMBER 12, 2021
The EMA’s human medicines committee has recommended approval of Roche’s Ronapreve and Celltrion’s Regkirona for use in COVID-19, the first antibody-based therapies for coronavirus to be backed for full approval in the EU.
COVID-19 neutralising antibody tests – an integrated approach
Pharma Phorum
JULY 6, 2021
Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies.
From Alpha to Epsilon: Consortium study illuminates surfaces of Spike most resistant to antibody escape
Scienmag
SEPTEMBER 23, 2021
LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates.
Antibodies mimicking the virus may explain long haul COVID-19, rare vaccine side effects
Scienmag
NOVEMBER 24, 2021
Latest News Antibodies COVID19 effects explain haul long Mimicking rare side vaccine virusWith around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field. Researchers are working to find effective vaccines and therapies, as well as understand the long-term effects of the infection. With around 256 million cases and more than 5 million deaths worldwide, […].
Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push
Bio Pharma Dive
NOVEMBER 5, 2020
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround
US stocks up on COVID-19 antibody drugs amid shortage concerns
Bio Pharma Dive
SEPTEMBER 15, 2021
Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months
5 Benefits of Monoclonal Antibodies
Pharma Focus Asia
OCTOBER 5, 2021
Antibody development has dramatically changed the pharmaceutical world, allowing for the creation of life-saving drugs and improvements to healthcare that would otherwise be impossible. The post 5 Benefits of Monoclonal Antibodies first appeared on Pharma Focus Asia.
F.D.A. Authorizes Another Antibody Treatment
NY Times
FEBRUARY 9, 2021
internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.
One dose of Regeneron’s COVID antibody protects for eight months
Pharma Phorum
NOVEMBER 8, 2021
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on.
Monoclonal Antibodies Shine in the Fight Against COVID-19
BioSpace
NOVEMBER 17, 2021
Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19
Antibody-Mediated Rejection Epidemiology Forecasts, 2030 – ResearchAndMarkets.com
BioTech 365
NOVEMBER 30, 2021
Antibody-Mediated Rejection Epidemiology Forecasts, 2030 – ResearchAndMarkets.com Antibody-Mediated Rejection Epidemiology Forecasts, 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Antibody-Mediated Rejection – Epidemiology Forecast 2030” report has been added to ResearchAndMarkets.com’s offering.
What level of antibody response protects against COVID-19 death?
Scienmag
OCTOBER 5, 2021
Medicine & Health antibody COVID19 death level protects response
In multiple myeloma, cell therapies lead but antibody drugs could follow fast
Bio Pharma Dive
DECEMBER 8, 2020
But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.
Delta and Delta Plus evade the antibody response
Scienmag
OCTOBER 15, 2021
Cancer antibody Delta evade responseThe emergence of new SARS-CoV-2 variants that can spread rapidly and undermine vaccine-induced immunity threatens the end of the COVID-19 pandemic. The delta variant (B.1.617.2) emerged in India and subsequently spread globally within a short time period.
AZ files for emergency use of COVID-19 antibody combo in US
Pharma Phorum
OCTOBER 5, 2021
AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy patients. The post AZ files for emergency use of COVID-19 antibody combo in US appeared first on.
Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use
Antibody delivery technology empowers immunotherapy against glioblastoma and suppresses side effects
Scienmag
OCTOBER 11, 2021
Summary: •An antibody delivery technology was developed based on multiple glucosylated polymers conjugated onto antibodies via linkers cleaving in tumor microenvironment. Biology antibody delivery effects empowers glioblastoma immunotherapy side suppresses technology
Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback
Bio Pharma Dive
SEPTEMBER 14, 2020
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020
Regeneron enlists Roche to boost production of COVID-19 antibody drug
Bio Pharma Dive
AUGUST 19, 2020
Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own
Boehringer goes after antibody cancer drugs in latest acquisition
Bio Pharma Dive
DECEMBER 10, 2020
billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy For about $1.4
Antibody protects against broad range of COVID-19 virus variants
Scienmag
AUGUST 21, 2021
Many of the variants circulating now are partially resistant to some of the antibody-based therapeutics that were developed based on the original virus. Medicine & Health MONOCLONAL ANTIBODIES SPIKE GLYCOPROTEIN
Regeneron warns its antibody drug may be less potent versus omicron
Bio Pharma Dive
NOVEMBER 30, 2021
While Regeneron is still testing its treatment against the new variant, the biotech is readying contingency plans, including second-generation versions of its drug
Eli Lilly’s COVID-19 Monoclonal Antibodies Cleared to Battle Delta
XTalks
SEPTEMBER 7, 2021
After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant.
Twist Bioscience Acquires Abveris to Complement Antibody Capabilities
BioSpace
NOVEMBER 21, 2021
Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. The acquisition is expected to bolster Twist’s biopharma antibody capabilities in a deal valued at up to $190 million.
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope
Pharma Phorum
MARCH 30, 2021
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on.
US signs $1bn order for GSK, Vir’s COVID-19 antibody
Pharma Phorum
NOVEMBER 17, 2021
The US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology’s antibody-based COVID-19 treatment sotrovimab said to be worth approximately $1 billion. The post US signs $1bn order for GSK, Vir’s COVID-19 antibody appeared first on.
Vir breaks through with study success for COVID-19 antibody
Bio Pharma Dive
MARCH 11, 2021
A data monitoring board said a study testing Vir's drug should be stopped early because of an overwhelming benefit from treatment
AstraZeneca Will Unite Vaccines, Antibody Therapies in New Division
BioSpace
NOVEMBER 8, 2021
AstraZeneca announced its plans to create a new, separate division for vaccines and antibody therapies, specifically its COVID-19 vaccine developed with the University of Oxford and other COVID-19 antibody treatments
Let's personalize your content